知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.013 秒)

    Method of affecting a function of or ablating a non-malignant cell
    3.
    发明授权
    Method of affecting a function of or ablating a non-malignant cell 有权
    影响非恶性细胞功能或消融的方法

    公开(公告)号：US07811570B2

    公开(公告)日：2010-10-12

    申请号：US11229872

    申请日：2005-09-20

    申请人： David M. Goldenberg

    发明人： David M. Goldenberg

    IPC分类号： A61K39/395

    CPC分类号： G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

    摘要： Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

    摘要翻译： 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

    Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy
    6.
    发明申请
    Immunoconjugates made of egg-yolk antibodies (igy), production and use thereof in diagnoses and therapy 审中-公开
    由蛋黄抗体（igy）制成的免疫缀合物，其诊断和治疗的生产和应用

    公开(公告)号：US20040236076A1

    公开(公告)日：2004-11-25

    申请号：US10478381

    申请日：2004-06-29

    发明人： Wolfgang Bergter ,  Hartmut Kobilke ,  Joachim Sroka

    IPC分类号： C07K016/18

    CPC分类号： B82Y5/00 ,  A61K41/0057 ,  A61K41/0071 ,  A61K47/6898 ,  A61K51/1006 ,  A61K51/1027 ,  A61K51/1036 ,  A61K51/1093

    摘要： The present invention relates to immunoconjugates from egg-yolk antibodies (IgY), their production and application in diagnostics and therapy. It is an object of the present invention to propose alternative products to conventional immunoconjugates for diagnostic and therapeutic use. The immunoconjugates in accordance with the invention are superior to monoclonal antibodies and immunosera from mammals, as well as to the IgY compounds from conventional chickens, in respect of purity and antigen targeting. The production of human anti-IgY-antibodies is to be avoided if possible, and the immunoconjugates are to be producible economically in a manner doing justice to animal protection and in large quantities. In accordance with the invention, the object is accomplished by polyclonal IgY conjugates from intact egg-yolk antibodies (IgY), IgY fragments, Fab constructs or humanized egg-yolk antibodies from SPF-chickens, preferably transgenic SPF-chickens. The antigens or antigen fragments are to be conjugated as immunologically effective component with at least one further component which may be a signal agent, an active agent or a booster molecule.

    摘要翻译： 本发明涉及来自蛋黄抗体（IgY）的免疫缀合物，其在诊断和治疗中的生产和应用。 本发明的目的是提供用于诊断和治疗用途的常规免疫缀合物的替代产物。 根据本发明的免疫缀合物在纯度和抗原靶向方面优于来自哺乳动物的单克隆抗体和免疫球蛋白以及来自常规鸡的IgY化合物。 如果可能，应避免生产人类抗IgY抗体，免疫缀合物经济地以对动物保护和大量正常的方式生产。 根据本发明，目的是通过来自SPF-鸡，优选转基因SPF鸡的完整卵黄抗体（IgY），IgY片段，Fab构建体或人源化卵黄抗体的多克隆IgY缀合物实现。 抗原或抗原片段应与免疫学有效成分共轭，其中至少一种其它组分可以是信号试剂，活性剂或加强分子。

    Method and kit for imaging and treating organs and tissues
    8.
    发明申请
    Method and kit for imaging and treating organs and tissues 审中-公开
    用于成像和治疗器官和组织的方法和试剂盒

    公开(公告)号：US20020052594A1

    公开(公告)日：2002-05-02

    申请号：US10002211

    申请日：2001-12-05

    申请人： IMMUNOMEDICS, INC.

    发明人： Milton D. Goldenberg

    IPC分类号： A61N001/30 ,  A61B005/05 ,  A61M031/00

    CPC分类号： G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

    摘要： Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

    摘要翻译： 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

    Genetic induction of receptors for targeted radiotherapy
    9.
    发明授权
    Genetic induction of receptors for targeted radiotherapy 失效
    用于靶向放射治疗的受体的遗传诱导

    公开(公告)号：US5981504A

    公开(公告)日：1999-11-09

    申请号：US948132

    申请日：1997-10-09

    申请人： Donald J. Buchsbaum ,  David Raben ,  Mohammad B. Khazaeli ,  David T. Curiel ,  Murray Stackhouse

    发明人： Donald J. Buchsbaum ,  David Raben ,  Mohammad B. Khazaeli ,  David T. Curiel ,  Murray Stackhouse

    IPC分类号： A61K51/08 ,  A61K51/10 ,  A61P35/00 ,  A61K48/00

    CPC分类号： A61K51/1036 ,  A61K51/08 ,  A61K51/083 ,  A61K51/10 ,  A61K2123/00

    摘要： The present invention provides a method to achieve radioisotopic localization at tumor sites, i.e., a method of enhancing radiolabeled ligand localization to a tumor in an individual in need of such treatment, comprising the steps of: transducing said tumor with a gene encoding a membrane expressed protein unique to said tumor; and administering to said individual a radiolabeled ligand which specifically binds to said protein. The use of gene therapy technology to induce expression of high affinity membrane molecules/receptors can enhance the specificity of radioisotope localization while the use of radioactive isotopes with the ability to deliver radiation damage across several cell diameters will compensate for less than perfect transduction efficiency.

    摘要翻译： 本发明提供了一种在肿瘤部位实现放射性同位素定位的方法，即在需要这种治疗的个体中增强对肿瘤的放射性标记配体定位的方法，包括以下步骤：用编码膜表达的基因转导所述肿瘤 所述肿瘤独特的蛋白质; 并向所述个体施用特异性结合所述蛋白质的放射性标记的配体。 使用基因治疗技术诱导高亲和力膜分子/受体的表达可以增强放射性同位素定位的特异性，而使用具有在几个细胞直径上传递辐射损伤的能力的放射性同位素将补偿不到完美的转导效率。